


ENGOT-en7/MaNGO/AtTEnd



PHASE III DOUBLE-BLIND RANDOMIZED TRIAL OF ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN WOMEN WITH ADVANCED/RECURRENT ENDOMETRIAL CANCER

Atezolizumab Trial in Endometrial cancer

Principal Investigator: Nicoletta Colombo, Istituto Europeo di Oncologia - Milano


Sponsor: MaNGO - Mario Negri Institute - Milano

Supporter: F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co., Ltd



Status: First patient-in planned for **October 2018**

Study design



Sample size: 550 patients

Stratified by:

- Country of the experimental center
- Histological type (endometrioid vs. other types)
- Disease (recurrent disease vs advanced disease at primary diagnosis)
- MS status (MSS vs MSI vs non-evaluable)

Trial feasibility in AtTEnd network

Country	Group	No. Sites	Maximum expected no. of patients
ITALY	MaNGO	21	181
AUSTRIA	A-AGO	3	17
GERMANY	AGO	4	20
POLAND	PGOG	5	40
SPAIN	GEICO	10	64
SWITZERLAND	SAKK	8	74
UK	UK NCRI	25	164
JAPAN	JGOG	10	40
AUSTRALIA/NZ	ANZGOG	20	100
TOTAL		106	700

Study timelines

Study Duration: accrual 2 years

Follow-up: 2 years

Italy:

Approval: July 2018

First study initiation visit: 11 October 2018

First patient screened: 9 October 2018

European Countries:

Foreseen approvals: September – December 2018

Outside Europe:

Foreseen approvals: January – February 2019